Skip to main content

Advertisement

SpringerLink
Log in

Identification and Evaluation of Serum MicroRNA-29 Family for Glioma Screening

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Glioma is one of the most common primary central nervous system tumors with high mortality and poor 5-year survival rate. Current diagnostic methods for glioma were either invasive or expensive. MicroRNAs (miRNAs) are small non-coding RNAs which play an important part in the regulation of gene expression. Considering the fact that miRNAs are stable in serum, plasma, urine, and other body fluids, they show great promises to be convenient and non-invasive biomarkers for cancers. This study aimed at evaluating the availability of serum microRNA-29 (miR-29) family in screening of glioma. A meta-analysis was also performed to assess the predictive value of miR-29 family in multi-cancer screening. Serum samples were collected from 83 glioma patients at different stages and 69 healthy controls. RNA was extracted and the relative expression of serum miR-29 was acquired by qRT-PCR and calculated by Cycle threshold (Ct) with microRNA-24 as an internal control. In the meta-analysis, studies concerning the predictive value of miR-29 family in cancer were retrieved. The predictive value of serum miR-29 family for glioma was moderate (AUC = 0.74). But the predictive value of serum miR-29 family in high-graded glioma detection was sufficient (AUC = 0.81). Also, serum miR-29 family might not be applicable in early-stage glioma detection (AUC = 0.66). A high predictive value of miR-29 family in multi-cancer detection was observed from meta-analysis (AUC = 0.83). This study manifested that serum miR-29 family could be applied as a biomarker for high-graded glioma screening, but the sensitivity and specificity for low-graded glioma detection might not be sufficient. A meta-analysis concerning the predictive value of miR-29 family in multi-cancer detection concluded that miR-29 family might be a sufficient universal biomarker for cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W, Bleeker FE, Hoogenraad CC, Michiels E, Kros JM, van den Bent M, Smitt PA, French PJ (2010) Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 31(3):E1186–E1199. doi:10.1002/humu.21201

    Article  CAS  PubMed  Google Scholar 

  2. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110. doi:10.1016/j.ccr.2009.12.020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M (2006) Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2(9):494–503. doi:10.1038/ncpneuro0289, quiz 491 p following 516

    Article  PubMed  Google Scholar 

  4. Fan Z, Wu Y, Shen J, Zhan R (2013) Glutathione S-transferase M1, T1, and P1 polymorphisms and risk of glioma: a meta-analysis. Mol Biol Rep 40(2):1641–1650. doi:10.1007/s11033-012-2213-8

    Article  CAS  PubMed  Google Scholar 

  5. Nie S, Chen T, Yang X, Huai P, Lu M (2014) Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. Dis Esophagus : Off J Int Soc Dis Esophagus / ISDE. doi:10.1111/dote.12194

    Google Scholar 

  6. Reddy SP, Britto R, Vinnakota K, Aparna H, Sreepathi HK, Thota B, Kumari A, Shilpa BM, Vrinda M, Umesh S, Samuel C, Shetty M, Tandon A, Pandey P, Hegde S, Hegde AS, Balasubramaniam A, Chandramouli BA, Santosh V, Kondaiah P, Somasundaram K, Rao MR (2008) Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis. Clin Cancer Res: Off J Am Assoc Cancer Res 14(10):2978–2987. doi:10.1158/1078-0432.CCR-07-4821

    Article  CAS  Google Scholar 

  7. Nikiforova MN, Hamilton RL (2011) Molecular diagnostics of gliomas. Arch Pathol Lab Med 135(5):558–568. doi:10.1043/2010-0649-RAIR.1

    CAS  PubMed  Google Scholar 

  8. McNamara MG, Sahebjam S, Mason WP (2013) Emerging biomarkers in glioblastoma. Cancer 5(3):1103–1119. doi:10.3390/cancers5031103

    Article  CAS  Google Scholar 

  9. Meister G (2007) MiRNAs get an early start on translational silencing. Cell 131(1):25–28. doi:10.1016/j.cell.2007.09.021

    Article  CAS  PubMed  Google Scholar 

  10. Zen K, Zhang CY (2012) Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 32(2):326–348. doi:10.1002/med.20215

    Article  PubMed  Google Scholar 

  11. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834–838. doi:10.1038/nature03702

    Article  CAS  PubMed  Google Scholar 

  12. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer J Int Cancer 127(1):118–126. doi:10.1002/ijc.25007

    Article  CAS  Google Scholar 

  13. Wang F, Wang XS, Yang GH, Zhai PF, Xiao Z, Xia LY, Chen LR, Wang Y, Wang XZ, Bi LX, Liu N, Yu Y, Gao D, Huang BT, Wang J, Zhou DB, Gong JN, Zhao HL, Bi XH, Yu J, Zhang JW (2012) miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep 39(3):2713–2722. doi:10.1007/s11033-011-1026-5

    Article  CAS  PubMed  Google Scholar 

  14. International ethical guidelines for biomedical research involving human subjects (2002) Bulletin of medical ethics 182:17–23

  15. Sobin LH, Fleming ID (1997) TNM classification of malignant tumors, fifth edition (1997). Union internationale contre le cancer and the American joint committee on cancer. Cancer 80(9):1803–1804

    Article  CAS  PubMed  Google Scholar 

  16. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11(2):193–206. doi:10.1037/1082-989X.11.2.193

    Article  PubMed  Google Scholar 

  17. Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58(9):882–893. doi:10.1016/j.jclinepi.2005.01.016

    Article  PubMed  Google Scholar 

  18. Fang C, Zhu DX, Dong HJ, Zhou ZJ, Wang YH, Liu L, Fan L, Miao KR, Liu P, Xu W, Li JY (2012) Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol 91(4):553–559. doi:10.1007/s00277-011-1350-9

    Article  CAS  PubMed  Google Scholar 

  19. Maclellan SA, Lawson J, Baik J, Guillaud M, Poh CF, Garnis C (2012) Differential expression of miRNAs in the serum of patients with high-risk oral lesions. Cancer Med 1(2):268–274. doi:10.1002/cam4.17

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhao M, Shen XK, Zhan P, Lv CF, Liu HB, Song Y (2012) Expression of miRNA-29a in non-small cell lung cancer and clinical significance. Chin Clin Oncol 17(05):428–432

    Google Scholar 

  21. Zhu HT, Dong QZ, Sheng YY, Wei JW, Wang G, Zhou HJ, Ren N, Jia HL, Ye QH, Qin LX (2012) MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS One 7(12):e52393. doi:10.1371/journal.pone.0052393

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Luo X, Stock C, Burwinkel B, Brenner H (2013) Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS One 8(5):e62880. doi:10.1371/journal.pone.0062880

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R (2013) Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma 54(1):189–191. doi:10.3109/10428194.2012.704030

    Article  CAS  PubMed  Google Scholar 

  24. Zheng JJ, Yu FJ, Dong PH, Bai YH, Chen BC (2013) Expression of miRNA-29b and its clinical significances in primary hepatic carcinoma. Zhonghua Yi Xue Za Zhi 93(12):888–891

    CAS  PubMed  Google Scholar 

  25. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res : Off J Am Assoc Cancer Res 12(19):5698–5704. doi:10.1158/1078-0432.CCR-06-0181

    Article  CAS  Google Scholar 

  26. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 104(40):15805–15810. doi:10.1073/pnas.0707628104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM (2006) Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 66(24):11590–11593. doi:10.1158/0008-5472.CAN-06-3613

    Article  CAS  PubMed  Google Scholar 

  28. Cho WC (2007) OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 6:60. doi:10.1186/1476-4598-6-60

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China, no. NSFC30801417; Natural Science Foundation of Jiangsu Province, nos. BK20141324 and BK2008267; Doctoral Fund of Ministry of Education of China, no. RFDP200802841004; and Medical Science and Technology Development Foundation, Nanjing Department of Health (no. ZKX12011).

Conflicts of Interest

The authors have declared no conflicts of interest.

Author information

Authors and Affiliations

  1. The Affiliated Drum Tower Hospital, Medical School, Nanjing University, Hankou Road 22#, Nanjing, Jiangsu, 210093, China

    Junhua Wu & Chunping Jiang

  2. School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China

    Liwen Li

Authors
  1. Junhua Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liwen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chunping Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chunping Jiang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, J., Li, L. & Jiang, C. Identification and Evaluation of Serum MicroRNA-29 Family for Glioma Screening. Mol Neurobiol 52, 1540–1546 (2015). https://doi.org/10.1007/s12035-014-8937-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-014-8937-9

Keywords

Search

Navigation